News ImmuneRegen NewsIR BioSciences Appoints Celgene Executive Dr. Robert Hariri to Its Board of DirectorsTuesday April 24, 6:00 pm ET SCOTTSDALE, AZ--(MARKET WIRE)--Apr 24, 2007 -- IR BioSciences Holdings, Inc. (OTC BB:IRBO.OB - News) announced today that it has appointed Robert J. Hariri, M.D., Ph.D. to its Board of Directors. Dr. Hariri is the Chief Executive Officer, of Celgene Cellular Therapeutics, a division of Celgene Corp., a world leader in human cellular and tissue therapeutics and a company with a market capitalization of more than $21 Billion. Dr. Hariri is a highly successful entrepreneur, has extensive experience in the capital markets and in developing start-up companies into highly successful commercial operations. He also has been extensively published in leading medical and scientific publications. This year he was named the National Multiple Sclerosis Pharmaceutical Executive of the Year. Last year, he was the recipient of the Thomas Alva Edison Patent Award. He has also received many other awards for his medical and entrepreneurial accomplishments. Dr. Hariri has been CEO of a division of Celgene since 2005. Previously, he had been President of the division from 2002 to 2005. The division focuses on human stem and biomaterial solutions for a range of clinical indications. Prior to joining Celgene, Dr. Hariri was Founder, Chairman and Chief Scientific Officer for Anthrogenesis Corp./LIFEBANK, Inc., a New Jersey-based privately held biomedical technology and service corporation involved in umbilical cord blood banking and its supporting technology platform. LIFEBANK is one of the largest cord blood bank companies and is recognized as a technological leader in the industry. "I am delighted to welcome such an accomplished and experienced executive to our Board of Directors," said IR BioSciences' CEO Michael Wilhelm. "It is not often that an emerging biotechnology company can attract a prominent executive such as Dr. Hariri to support its development activities. I look forward to working closely with him as we continue the development of Radilex(TM), Viprovex(TM) and other programs." Dr. Hariri has held academic positions at Cornell University Medical College Cornell University Graduate School of Medical Sciences. He has also played a prominent medical role at Cornell University Medical College, The New York Hospital-Cornell Medical Center and The Jamaica Hospital-Cornell Trauma Center. While at Cornell, he was the Director of The Center for Trauma Research. He received his Medical Degree and Ph.D from Cornell University and was awarded a Bachelor of Arts Degree from Columbia College.
About ImmuneRegen BioSciences, Inc.a wholly owned subsidiary of IR BioSciences Holdings, Inc., (OTC BB:IRBS.OB - News) is a development-stage biotechnology company focused on the research, development and licensing of Homspera™ and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com. Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements. Contact: or
### Copyright © 2003-2008, ImmuneRegen Biosciences, Inc. All rights reserved. |
|